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Background. Oropharyngeal candidiasis is the most common opportunistic infection affecting patients with
human immunodeficiency virus (HIV) infection. Because of convenience, cost, and reluctance to complicate
antiretroviral treatment regimens, single-dose fluconazole may be a favorable regimen for treatment of moderate
to severe oropharyngeal candidiasis. We conducted a prospective, randomized, double-blind, placebo-controlled
trial to compare the clinical and mycological responses, relapse rates, and safety of a single 750-mg dose and a
14-day course of treatment with fluconazole.
Methods. A total of 220 HIV-infected patients with clinical and mycological evidence of oropharyngeal can-
didiasis were randomly assigned in a 1:1 ratio to receive either a 750-mg single dose of orally administered
fluconazole (110 patients) or 150 mg of orally administered fluconazole once per day for 2 weeks (110 patients).
The primary efficacy analysis was based on clinical and mycological responses at the end of treatment. Secondary
parameters were safety and relapse rate.
Results. Single-dose fluconazole was equivalent to a 14-day course of fluconazole in achieving clinical and
mycological cure, with clinical cure rates of 94.5% and 95.5%, respectively (odds ratio, 0.825; 95% confidence
interval, 0.244–2.789; ), and mycological cure rates of 84.5% and 75.5%, respectively (odds ratio, 1.780;Pp .99
95% confidence interval, 0.906–3.496; ). Drug-related adverse events were uncommon and were notPp .129
different between the treatment groups.
Conclusion. A single dose of 750 mg of fluconazole was safe, well tolerated, and as effective as the standard
14-day fluconazole therapy in patients with HIV infection and acquired immunodeficiency syndrome who had
oropharyngeal candidiasis coinfection.
Trial registration. ClinicalTrials.gov identifier: NCT00553137.
Oropharyngeal candidiasis (OPC) has been reported to
occur in up to 90% of subjects infected with HIV;
therefore, OPC is the most commonly encountered op-
portunistic infection in these patients [1, 2]. As a result
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of HAART, the incidence and prevalence of most op-
portunistic infections has greatly decreased [3, 4]. How-
ever, OPC remains the most frequent HIV-associated
oral disease in sub-Saharan Africa, where access to
HAART is still limited [5, 6].
The occurrence of OPC is associated with low CD4
T lymphocyte numbers, high viral loads, and disease
progression [1, 4, 7], but at the same time, OPC tends
to be one of the first opportunistic infections seen in
patients with CD4 T lymphocyte levels !200 cells/mm3.
In Tanzania, fluconazole, at a dose of 150 mg once
per day for 2 weeks, is included in the guidelines for
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the treatment of OPC in HIV-infected patients [8]. Treatment
with fluconazole achieved complete clinical response in 87%–
100% of patients and was effective in obtaining a mycological
cure in 53%–87% of patients after a 7-, 14-, or 28-day course
of therapy [9– 14]. Single-dose fluconazole (150 mg) therapy
has been reported to lead to complete clinical response in 75%–
100% of patients and mycological eradication of Candida spe-
cies in 6%–41%, whereas 30%–38.5% of patients experienced
relapse during follow-up after treatment [15–17]. However, the
single-dose fluconazole studies involved a limited number of
patients, may have been performed with a suboptimal flucon-
azole dose, and did not make use of a randomized study design.
Because of convenience, cost, and reluctance to complicate an-
tiretroviral treatment regimens, single-dose fluconazole may be
a more favorable regimen for treatment of HIV-associated OPC
than the recommended dose of 150 mg of fluconazole once
per day, administered orally, for 2 weeks [8]. The aim of our
study was to determine whether a single dose of 750 mg of
fluconazole was as effective as the standard 14-day course of
fluconazole for the treatment of OPC in HIV-infected patients.
PATIENTS AND METHODS
Patients. Participants were recruited at the HIV clinic of the
Muhimbili National Hospital (Dar es Salaam, Tanzania) from
November 2006 through December 2007. Patients were eligible
for the study if they met the following criteria: 18 years of
age, with documented HIV infection (as determined by positive
ELISA results and confirmed by Western-blot analysis); clinical
symptoms of OPC; characteristic visual lesions; and microbi-
ological confirmation.
Patients were excluded from study participation for any of
the following reasons: ongoing or previous topical or systemic
antifungal therapy within 3 days before study enrollment; a
history of allergy to azole derivatives; abnormal results of liver
function tests, defined as alanine aminotransferase (ALT), as-
partate aminotransferase (AST), or direct or total bilirubin lev-
els 13 times the upper limit of normal; evidence of significant
hepatic or renal disease within 2 months before study enroll-
ment; inability to tolerate oral drug administration; current
pregnancy or breast feeding; life expectancy of !4 weeks; cur-
rent participation in another clinical trial; current treatment
with drugs that are known to interact with fluconazole; doc-
umented systemic fungal infection; and symptoms suggestive
of esophageal candidiasis. Also, patients with a history of al-
cohol abuse, drug addiction, psychiatric disorders, inability to
cooperate, and poor motivation were excluded from the study.
The study was performed in accordance with good clinical
practices and the principles set forth in the World Medical
Assembly Declaration of Helsinki. The Ethics Committee of
the Muhimbili University of Health and Allied Sciences and
Muhimbili National Hospital approved the study protocol, and
each patient signed a written statement of informed consent
before enrollment and receipt of study medication.
Study design and procedures. We conducted a prospective,
randomized, double-blind, double-dummy trial to compare the
clinical and mycological responses, relapse rates, and safety of
2 regimens of fluconazole therapy for treatment of OPC in
HIV-infected patients. Eligible patients were randomized in a
1:1 ratio to 1 of the 2 treatment groups on the basis of a
predefined randomization code. The pharmacist, who dis-
pensed the medicine, held the randomization code, and neither
the evaluator nor the patients had knowledge of what treatment
was given. Patients were randomized to receive oral treatment
of a single dose of 750 mg (5 tablets of 150 mg) of fluconazole
and 1 placebo tablet once per day for 2 weeks or a standard
regimen of orally administered fluconazole (1 tablet of 150 mg)
once per day for 2 weeks [8]. These patients also received 5
placebo tablets on the first day of therapy. After the baseline
visit on day 0, visits were scheduled for day 3 or 4, day 6 or
7, day 14 (end of therapy), and day 42 (follow-up). At baseline,
a structured standard questionnaire was used to systematically
collect demographic information, medical history, treatment
history, concomitant illness(es), and current treatments. Gen-
eral and oral examinations were performed at baseline and at
subsequent visits, with use of a standard oral examination
method [18]. On days 3 or 4, 6 or 7, and 14, patients were
examined and assessed for signs and symptoms, adverse drug
effects, and compliance with the regimen. Clinical adverse ef-
fects were recorded at each visit and were graded as mild,
moderate, or severe. Patients were asked to bring the remaining
study medication during follow-up visits, and pill count was
performed by a pharmacist and the result was recorded. Follow-
up examinations in both treatment groups were performed on
day 42 or earlier if patients experienced relapse. A single ex-
aminer evaluated all patients throughout the trial.
Oral swab specimens were obtained at baseline for diagnosis,
on day 14 for mycological evaluation, and on day 42 or earlier
when there was evidence of a relapse of OPC. Specimens were
obtained by firmly swabbing the lesion site with a sterile cotton-
wool swab [19]. The swabs were sent immediately to the lab-
oratory for microbiological confirmation. Isolates were iden-
tified to the species level, and antifungal susceptibility to
fluconazole was assessed according to the guidelines of the
Clinical and Laboratory Standards Institute [20].
Blood samples were obtained at baseline for determination
of basic hematology, for biochemical tests, and to assess CD4
and CD8 cell counts. Blood samples were also obtained at the
end of treatment (day 14) for hematology and biochemical tests.
Also, blood samples from 25 randomly selected patients (13
patients receiving a single-dose and 12 receiving standard ther-
apy) were obtained at baseline, on day 1, on day 4 or 5, on
day 7, and on day 14, for determination of fluconazole plasma
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concentrations. Fluconazole plasma concentrations were mea-
sured by means of protein precipitation followed by tandem–
mass spectrometric detection, with use of internal standard and
spiked-pool serum samples as controls.
Efficacy evaluations. The efficacy of each of the 2 treatment
regimens was assessed by comparison of primary outcome mea-
sures that included clinical and mycological responses at the
end of treatment. The severity of signs and symptoms at base-
line and at the end of therapy and the extent of lesions were
graded and scored. Lesions were monitored with assistance of
oral-cavity diagrams for estimating lesion sizes and locations.
The overall OPC clinical score based on signs, symptoms, and
extent of lesions was graded as absent (no symptoms or lesions
present), mild (scattered, nonconfluent lesions 12 mm in size),
moderate (multiple lesions 12 mm in size), and severe (exten-
sive, confluent lesions). Clinical responses were defined as cured
(complete resolution of lesions, signs, and symptoms of OPC),
improved (a reduction in the number of lesions and symptoms
but persisting typical oropharyngeal lesions), or failed (no res-
olution of signs and symptoms; i.e., either no change or OPC
that has progressed). In evaluation of results of mycological
cultures on day 14, any growth of Candida species was classified
as mycological treatment failure.
Secondary outcome measures included relapse of OPC and
safety of the 2 fluconazole regimens. Relapse was defined as an
initial cure followed by reappearance of symptoms, clinical
signs of OPC, and/or confirmation by positive yeast culture
during a follow-up period of 4 weeks after the end of treatment.
Patients with a clinical evaluation of “cured” on day 14 were
considered to have a successful outcome and were eligible for
the follow-up phase.
Safety evaluations. Safety and tolerability were assessed by
the observation of adverse events. Baseline and posttreatment
blood investigations included biochemical tests and full blood
count and were compared between the 2 regimens.
Statistical analysis. This trial was designed to have 80%
power to demonstrate equivalence (within 20%) in clinical re-
sponse between the 2 fluconazole regimens, and 95% CIs of
the difference in response rates were used in determination of
equivalence. Data were analyzed using SPSS, version 14.0
(SPSS). Comparisons between the 2 treatment groups were
performed using Student’s t test whenever continuous variables
were normally distributed; for skewed distributions, the Mann-
Whitney U test was used. Noncontinuous categorical and or-
dinal variables were analyzed using Fisher’s exact test. The re-
sults of posttreatment liver function test and full blood count
were compared (between the 2 fluconazole regimens) by anal-
ysis of covariance, with the pretreatment test result as a co-
variate. All statistical tests were 2 tailed, and exact probabilities
were reported for each test.
RESULTS
Demographic baseline and clinical characteristics. A total of
220 patients were randomized to either the single-dose flucon-
azole group (110 patients) or the 14-day fluconazole group
(110 patients). The baseline clinical and demographic charac-
teristics were similar in both treatment groups (table 1). The
median CD4 cell count, World Health Organization HIV clin-
ical stage, and OPC clinical score were similar in all treatment
groups. More than one-half of patients in both treatment
groups were not receiving antiretroviral therapy at baseline.
Eighty (36.4%) of 220 patients were receiving HAART, which
comprised combinations as follows: stavudine, lamivudine, and
nevirapine in 57 patients (71.3%); zidovudine, lamivudine, and
efavirenz in 20 patients (25.0%); and zidovudine, lamivudine,
and nevirapine in 2 patients (2.5%). One patient (1.3%) was
receiving stavudine, didanosine, and ritonavir-lopinavir. More
than one-half of the patients (40 patients; 55%) had received
HAART for !3 months. With regard to previous exposure to
azole antifungal agents, the proportions were also equal be-
tween the 2 treatment groups. As measured by the pill counts,
all 220 patients were highly compliant with the study treatment
regimens.
Baseline mycological findings and susceptibility testing.
Candida albicans comprised 90% of pretreatment isolates, and
there were no statistically significant differences in species dis-
tribution and MICs of fluconazole between the treatment
groups at baseline ( ).Pp .823
Efficacy Analysis
All 220 enrolled patients were evaluable for clinical and my-
cological responses.
Clinical efficacy. In the 14-day fluconazole group, 105 pa-
tients (95.5%) were considered to be clinically cured, 4 patients
(3.6%) had improved clinically, and 1 (0.9%) experienced treat-
ment failure. In the single-dose fluconazole group, 104 patients
(94.5%) were considered to be clinically cured, 2 patients
(1.8%) had improved clinically, and 4 patients (3.6%) expe-
rienced treatment failure. The difference in clinical success be-
tween the 2 treatment groups was not significant (OR, 0.825;
95% CI, 0.244–2.789; ). There was a significant asso-Pp .99
ciation between higher MICs for fluconazole at baseline and
poor clinical outcome ( ). There were no significantPp .016
associations between clinical outcome and CD4 cell count and
previous azole exposure ( and , respectively).Pp .089 Pp .805
Ninety patients with recurrent OPC at baseline (72.2%) had a
history of 1 previous episode of OPC, and the range of recur-
rences was 1–4 episodes. There were no statistically significant
associations between clinical outcome and number of previous
OPC episodes.
Mycological efficacy. At baseline, all enrolled patients had
positive results of both microscopy and culture. At the end of
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Table 1. Patient demographic and baseline characteristics.
Variable
Fluconazole treatment group
P a Test
14 Days
(n p 110)
Single dose
(n p 110)
All patients
(n p 220)
Sex
Male 27 (24.5) 26 (23.6) 53 (24.1) .99 F
Female 83 (75.5) 84 (76.4) 167 (75.9)
Mean age, years  SD (range) 35  8.1 (22–75) 34  7.9 (19–63) 34.8  8.0 (19–75) .130 t
Body mass index,b mean  SD (range) 20.9  4.0 (13.1–38.1) 21.0  3.3 (13.6–32.4) 20.9  3.7 (13.1–38.1) .908 t
Median CD4 cell count, cells/mm3 (range) 100 (3–689) 88 (2–614) 100 (2–689) .578 MW
World Health Organization stage
III 86 (78.2) 94 (85.5) 180 (81.8) .221 F
IV 24 (21.8) 16 (14.5) 40 (18.2)
OPC clinical score
Mild 6 (5.5) 4 (3.6) 10 (4.5) .835 F
Moderate 73 (66.4) 76 (69.1) 149 (67.7)
Severe 31 (28.2) 30 (27.3) 61 (27.7)
History of OPC
Primary 66 (60.0) 64 (58.2) 130 (59.1) .891 F
Recurrent 44 (40.0) 46 (41.8) 90 (40.9)
Pretreatment isolates
Candida albicans only 100 (90.9) 98 (89.1) 198 (90.0) .823 F
Candida krusei only 4 (3.6) 2 (1.8) 6 (2.7)
Candida glabrata only 2 (1.8) 3 (2.7) 5 (2.3)
Candida tropicalis 1 (0.9) 4 (3.6) 5 (2.3)
Candida kefyr 2 (1.8) … 2 (0.9)
C. albicans and C. krusei … 2 (1.8) 2 (0.9)
C. glabrata and C. krusei 1 (0.9) 1 (0.9) 2 (0.9)
Prior azoles antifungal exposure 56 (50.9) 56 (50.9) 112 (50.9) .99 F
Use of HAART
Yes 39 (35.5) 41 (37.3) 80 (36.4) .889 F
No 71 (64.5) 69 (62.7) 140 (63.6)
NOTE. All data are no. (%) of patients, unless otherwise indicated. F, Fisher’s exact test; MW, Mann-Whitney U test; OPC, oropharyngeal candidiasis; t,
Student’s t test.
a A 14-day course of fluconazole compared with a single dose of fluconazole.
b Calculated as weight in kilograms divided by the square of height in meters.
treatment, mycological cure was achieved in 83 patients
(75.5%) in the 14-day fluconazole group and in 93 patients
(84.5%) in the single-dose fluconazole group. Mycological fail-
ure was observed in 27 patients (24.5%) in the 14-day flucon-
azole treatment group and in 17 patients (15.5%) in the single-
dose fluconazole group. There was no significant difference in
mycological cure rates between patients receiving the 2 flucon-
azole regimens (OR, 1.780; 95% CI, 0.906–3.496; ).Pp .129
The mean MICs of fluconazole for these isolates were not sig-
nificantly different between the 2 treatment groups ( ).Pp .318
Overall, in 11 patients, clinical cure was not achieved, and for
all of these, Candida species were isolated from patient speci-
mens at baseline and on day 14. In 33 patients (15.0%), clinical
cure was obtained despite persistent positive culture results on
day 14 (mycological failure).
Relapse. Relapse was analyzed in the 194 patients who
completed the follow-up phase of the study. The reasons for
discontinuation during the follow-up phase were death related
to advanced stage of HIV infection and AIDS (4 patients), loss
to follow-up (11 patients), and administration of additional
treatment for OPC because of failure of the primary therapy
(11 patients). No difference was observed in relapse rates be-
tween the evaluable patients from the 14-day and single-dose
fluconazole groups (OR, 1.073; 95% CI, 0.456–2.523; Pp
) (table 2). The average time to relapse after clinical cure.99
was 20 days (range, 7–30 days) in the 14-day fluconazole group,
compared with 18 days (range, 1430 days) in the single-dose
fluconazole group. Twenty-two (91.7%) of 24 patients who
experienced relapse during follow-up had CD4 cell counts !200
cells/mm3, 16 (66.7%) had CD4 cell counts !100 cells/mm3,
17 (70.8%) were not receiving HAART, and 14 (58.3%) had
had previous episodes of OPC.
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Figure 1. Plasma fluconazole concentrations in HIV-positive patients
with oropharyngeal candidiasis who received treatment with a single
dose (750 mg) or a 14-day course (150 mg once per day) of fluconazole.
Plasma concentrations were significantly different on days 1, 7, and 14
( ) but not on day 4 ( ).P ! .01 Pp .23
Table 2. Evaluation of oropharyngeal candidiasis (OPC) relapse during the
follow-up period after fluconazole treatment.
Variable
No. (%) of patients
14-Day course of
fluconazole
(np 100)
Single dose of
fluconazole
(np 94)
Full cohort
(np 194)
OPC relapse 12 (12) 12 (12.8) 24 (12.4)
No relapse 88 (88) 82 (87.2) 170 (87.6)
NOTE. n Values are numbers of evaluable patients. OR, 1.073; 95% CI, 0.456–2.523;
(Fisher’s exact test) for the difference in OPC relapse rates between patients receivingPp .99
a 14-day course (150 mg once per day) and patients receiving a single dose (750 mg) of
fluconazole.
Fluconazole plasma concentrations. The mean plasma flu-
conazole concentrations on days 1, 4 or 5, 7, and 14 in the 14-
day fluconazole group were 4.18, 6.88, 7.94, and 7.62 mg/L,
respectively; for the single-dose fluconazole group, the con-
centrations were 13.35, 5.46, 1.37, and 0.32 mg/L, respectively
(figure 1). There were statistically significant differences in
mean plasma concentrations between the 2 treatment groups
on days 1, 7, and 14 but not on day 4 or 5 (figure 1). Fluconazole
exposure was greater for patients who received the single dose
of fluconazole, at least until day 4 or 5, compared with those
who received the 14-day course.
Safety analysis. Overall, adverse events were mild, and no
differences in frequency of adverse events were noted between
patients in the 2 treatment regimens. Adverse events were re-
ported in 6 patients (5.5%) in the 14-day fluconazole group;
all events were gastrointestinal. In the single-dose fluconazole
group, adverse events were reported in 8 patients (7.3%); 6
reported nausea, vomiting, abdominal pain, and/or diarrhea, 1
patient had headache, and 1 patient had heart palpitations and
dizziness. Because most of the study patients were in an ad-
vanced stage of HIV infection and AIDS, abnormalities in full
blood count and liver function tests were common (table 3).
However, no clinically significant changes in full blood count
and liver function parameters were observed after treatment in
either of the 2 treatment groups, with the exception of 1 patient
(0.9%) in the single-dose fluconazole group in whom ALT and
AST levels increased to 262 U/L and to 377 U/L, respectively,
without symptoms; later, ALT and AST levels returned to nor-
mal. This patient was taking the study drug while HAART
(stavudine, lamivudine, and nevirapine) was initiated concom-
itantly. None of the patients discontinued therapy because of
adverse events related to the study drug.
DISCUSSION
The results of the present study demonstrate that a single-dose
regimen of 750 mg was as effective as a standard 14-day flu-
conazole regimen in achieving clinical and mycological cure in
the treatment of OPC in patients with HIV infection and AIDS.
These results are in agreement with previous studies conducted
to assess the clinical and mycological efficacy of 14-day flu-
conazole for management of OPC in patients with HIV infec-
tion and AIDS, which demonstrated 87%–100% effectiveness
in obtaining a complete clinical response [9–14]. The myco-
logical cure rate, with a single-dose treatment of 750 mg flu-
conazole, was much higher (84.5%) than the 6%–41% my-
cological cure rates reported elsewhere [15–17] that made use
of a single dose of 150 mg of fluconazole. C. albicans was the
species most commonly isolated at baseline, at the end of ther-
apy, and during OPC recurrence for both treatment groups. In
addition, plasma fluconazole concentrations on day 1 were sig-
nificantly higher in patients receiving single-dose fluconazole;
however, until day 4 or 5, fluconazole exposures were similar
in both treatment groups. In this trial, similar efficacy was
found in maintaining a symptom-free period after the end of
therapy in both treatment groups. OPC relapses were observed
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Table 3. Baseline and posttreatment hematology and biochem-
ical test results of HIV-positive patients with oropharyngeal can-
didiasis treated with a single dose (750 mg) and a 14-day course
(150 mg once per day) of fluconazole.
Variable
Mean results by fluconazole
treatment group
Pa
14 Days Single dose
Baseline Day 14 Baseline Day 14
Hematology
Leukocytes, mL 103 5.04 4.61 5.05 4.52 .612
Erythrocytes, mL 106 3.99 4.04 4.03 4.08 .893
Hemoglobin, g/dL 10.49 10.76 10.51 10.91 .740
Platelets, mL 103 292.1 286.4 303.6 300.4 .428
ESR, mm/h 72 49 68 51 .260
Biochemical
ALP, U/L 109.7 109.3 97.7 102.8 .955
ALT, U/L 24.1 27.6 23.5 31.3 .134
AST, U/L 33.2 33.6 33.7 36.6 .320
BilD, mmol/L 3.7 3.1 3.23 3.4 .185
BilT, mmol/L 7.4 6.4 7.14 6.39 .987
LD, U/L 277.8 279.3 281.7 275.4 .535
Urea, mmol/L 3.6 3.4 3.7 3.6 .109
Uric acid, mmol/L 0.29 0.24 0.27 0.26 .360
NOTE. ALP, alkaline phosphatase; AST, aspartate aminotransferase; BilT,
total bilirubin; BilD, direct bilirubin; ESR, erythrocyte sedimentation rate; LD,
lactate dehydrogenase.
a Based on the F test, which is based on the linearly independent pairwise
comparisons among the estimated marginal means.
(12.4%) in both treatment groups, with the majority occurring
among patients who had low CD4 cell counts (!200 cells/mm3),
had previous episodes of OPC, and were not receiving HAART.
Antifungal prophylaxis for these patients may be considered in
addition to the provision of HAART [12, 21]. In addition, both
treatments had acceptable treatment tolerability and safety.
However, it was demonstrated that ALT and AST levels after
initiation of HAART among HIV-infected patients who con-
currently received nevirapine and fluconazole were not different
from levels of those who received nevirapine-based HAART
without fluconazole [22]. The elevation of ALT and AST levels
that was observed in 1 patient in the single-dose group in the
present study could be attributable to the effect of the nevi-
rapine component of the regimen, because liver toxicity caused
by nevirapine is well known [23, 24].
In the present study, reduced susceptibility to fluconazole at
baseline was found to be a significant factor associated with
treatment failure, irrespective of the treatment regimen used.
For fluconazole, several studies have shown a correlation be-
tween in vitro susceptibility and treatment outcome [25–27],
and interpretative breakpoints have been established [28]. Our
study also indicates that MIC testing of isolates at the time of
OPC diagnosis might be useful in patient management for
identification of those patients with an increased probability of
experiencing treatment failure.
The high percentage of patients receiving HAART who pre-
sented with OPC may suggest that the HAART regimens were
not effective. However, a recent study that was conducted at
the same hospital as our study and that involved some of our
patients found high patient compliance to therapy and ex-
tremely low rates of resistance to HAART [29]. The most plau-
sible explanation is that more than one-half of the patients
(55%) were receiving HAART for !3 months, and the majority
(86.3%) had low CD4 cell counts (!200 cells/mm3).
The use of a single high dose of fluconazole for the treatment
of OPC in patients with HIV infection and AIDS presents the
advantages of simplicity and convenience, thus improving com-
pliance and reducing the cost of therapy. A single dose of five
150-mg tablets is less costly than fourteen 150-mg tablets taken
over a 14-day course and, therefore, could be used, especially
in resource-limited settings like in sub-Saharan Africa. In ad-
dition, adminstration of the single-dose therapy can be ob-
served directly by medical personnel, thereby assuring patient
compliance.
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